Crossmark Global Holdings Inc. Acquires 14,487 Shares of Hologic, Inc. (NASDAQ:HOLX)

Crossmark Global Holdings Inc. lifted its holdings in shares of Hologic, Inc. (NASDAQ:HOLX) by 80.0% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 32,588 shares of the medical equipment provider’s stock after acquiring an additional 14,487 shares during the period. Crossmark Global Holdings Inc.’s holdings in Hologic were worth $2,349,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Benson Investment Management Company Inc. bought a new stake in shares of Hologic in the 4th quarter worth $4,832,000. Clean Yield Group grew its position in Hologic by 18.9% in the 4th quarter. Clean Yield Group now owns 45,646 shares of the medical equipment provider’s stock worth $3,291,000 after purchasing an additional 7,266 shares in the last quarter. GAMMA Investing LLC increased its stake in Hologic by 17.9% in the 3rd quarter. GAMMA Investing LLC now owns 3,832 shares of the medical equipment provider’s stock valued at $312,000 after buying an additional 582 shares during the last quarter. Janus Henderson Group PLC lifted its position in shares of Hologic by 2.9% during the 3rd quarter. Janus Henderson Group PLC now owns 28,776 shares of the medical equipment provider’s stock worth $2,344,000 after buying an additional 800 shares in the last quarter. Finally, Versor Investments LP purchased a new position in shares of Hologic in the 3rd quarter worth approximately $1,677,000. Institutional investors and hedge funds own 94.73% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages recently commented on HOLX. Needham & Company LLC reiterated a “buy” rating and set a $90.00 price target on shares of Hologic in a report on Monday, January 13th. Evercore ISI lifted their target price on Hologic from $78.00 to $82.00 and gave the stock an “in-line” rating in a research note on Tuesday, October 1st. Morgan Stanley reduced their price target on shares of Hologic from $84.00 to $82.00 and set an “equal weight” rating for the company in a research report on Monday, January 13th. Raymond James lifted their price objective on shares of Hologic from $93.00 to $95.00 and gave the stock an “outperform” rating in a research report on Tuesday, November 5th. Finally, Wolfe Research initiated coverage on shares of Hologic in a research note on Friday, December 13th. They set a “peer perform” rating for the company. Seven research analysts have rated the stock with a hold rating, nine have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, Hologic currently has a consensus rating of “Moderate Buy” and an average target price of $88.92.

Hologic Stock Down 0.7 %

Shares of NASDAQ HOLX opened at $70.70 on Friday. The company has a quick ratio of 3.03, a current ratio of 3.69 and a debt-to-equity ratio of 0.49. The company has a market cap of $15.96 billion, a P/E ratio of 21.23, a P/E/G ratio of 2.40 and a beta of 0.97. Hologic, Inc. has a 52 week low of $68.61 and a 52 week high of $84.67. The business has a 50-day simple moving average of $74.16 and a two-hundred day simple moving average of $78.25.

Hologic (NASDAQ:HOLX) last released its quarterly earnings data on Monday, November 4th. The medical equipment provider reported $1.01 EPS for the quarter, meeting analysts’ consensus estimates of $1.01. The company had revenue of $987.90 million during the quarter, compared to analyst estimates of $978.25 million. Hologic had a net margin of 19.59% and a return on equity of 19.79%. Hologic’s revenue was up 4.5% compared to the same quarter last year. During the same period last year, the business earned $0.89 earnings per share. Research analysts anticipate that Hologic, Inc. will post 4.27 earnings per share for the current fiscal year.

Insider Transactions at Hologic

In related news, COO Essex D. Mitchell sold 24,856 shares of the business’s stock in a transaction dated Wednesday, December 4th. The stock was sold at an average price of $76.34, for a total transaction of $1,897,507.04. Following the completion of the transaction, the chief operating officer now directly owns 27,957 shares in the company, valued at $2,134,237.38. The trade was a 47.06 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 1.88% of the company’s stock.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.